



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 15, 2021

Evan S. Melrose  
Chief Executive Officer  
Spindletop Health Acquisition Corp.  
7000 N. Mopac, Suite 315  
Austin, TX 78731

**Re: Spindletop Health Acquisition Corp.**  
**Registration Statement on Form S-1**  
**Filed March 19, 2021**  
**File No. 333-254531**

Dear Dr. Melrose:

We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Form S-1

Management, page 123

1. Please revise your disclosure to more specifically describe your officers' and directors' principal occupations and employment during the past five years. Please refer to Item 401(e) of Regulation S-K.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Evan S. Melrose  
Spindletop Health Acquisition Corp.  
April 15, 2021  
Page 2

You may contact Heather Clark, Staff Accountant, at (202) 551-3624 or Andrew Blume, Acting Accounting Branch Chief, at (202) 551-3254 if you have questions regarding comments on the financial statements and related matters. Please contact Sergio Chinos, Staff Attorney, at (202) 551-7844 or Jay Mumford, Special Counsel, at (202) 551-3637 with any other questions.

Sincerely,

Division of Corporation Finance  
Office of Manufacturing

cc: Jon Venick